Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands

L. M. Kool-Houweling, F. J. Penning-van Beest, I. D. Bezemer, R. A. van Lingen, R. M. Herings

Research output: Contribution to journalArticleAcademicpeer-review


AIM: Palivizumab is reported to be effective in reducing respiratory syncytial virus hospitalisation. Its licensed uses include infants younger than six months of age, born before 35 weeks of gestation or under two years old with congenital heart disease or bronchopulmonary dysplasia. We redressed lack of research in the Netherlands by studying whether infants who met the licensed indications received the drug. METHODS: Data were obtained from the PHARMO Database Network and The Netherlands Perinatal Registry for all linked infants born between 1 April 1999 and 31 March 2007. Determinants for receiving palivizumab were examined using logistic regression analyses. RESULTS: Only 15% of the 3321 infants who met the licensed indications received palivizumab and the strongest predictor was being born before 32 weeks of gestation, with an odds ratio of 49.1 (95% confidence interval 31.5-76.4). However, 50% of infants born before 32 weeks did not receive palivizumab and the subanalyses showed that the probability increased for infants born in later years, those who had respiratory distress syndrome and those hospitalised during the respiratory syncytial virus season. CONCLUSION: Only 15% of eligible infants in the Netherlands received palivizumab and they were mostly born before 32 weeks, in line with Dutch guidelines.
Original languageEnglish
Pages (from-to)927-932
Number of pages6
JournalActa Paediatrica
Issue number9
Publication statusPublished - 2015


  • Age Factors Antiviral Agents/*therapeutic use Case-Control Studies Female Hospitalization Humans Infant, Newborn Infant, Premature Infant, Premature, Diseases/*drug therapy Logistic Models Male Netherlands Palivizumab/*therapeutic use Patient Selection Practice Patterns, Physicians' Respiratory Syncytial Virus Infections/*drug therapy Retrospective Studies Determinants Observational database study Palivizumab Prematurity Respiratory syncytial virus

Cite this